Redaktion

Menschen mit Schuppenflechte auf der Kopfhaut brechen eine Salbenkur oft ab, dann wirkt sie schlechter.[1] In der PRO‑SCALP Studie testeten Ärzte eine neue Creme mit Calcipotriol und Betamethason für milde bis mittlere Kopfhautpsoriasis.[1] Etwa 60 Prozent nutzten die Creme sehr regelmäßig, diese Gruppe bekam deutlich klarere Kopfhaut und war zufriedener.[1][3] Auch Juckreiz und Schlaf wurden besser, die Lebensqualität stieg.[1][3] Wer die Creme seltener nutzte, merkte zwar auch eine Besserung, verpasste aber viel Wirkung.[3] Die einfache Botschaft lautet: Wer dranbleibt, hat auf der Kopfhaut die besten Chancen. Originaltitel: Adherence to CAL/BDP PAD-Cream Influences Treatment Effectiveness and Preference in Scalp Psoriasis Under Real-Life Conditions: Results from the Prospective, Multicenter, Observational PRO-SCALP Study. Link zur Quelle

Die Expertengruppe SPIN‑FRT sieht, dass viele zielgerichtete Therapien gegen Psoriasis und Neurodermitis auch bei bestehendem oder überstandenem Krebs eingesetzt werden können.[1][14][15] Die Entscheidung soll immer gemeinsam mit den Krebsärztinnen und ‑ärzten und Euch getroffen werden.[14][15] ### Was heißt das für Euch? Eine Krebsdiagnose bedeutet nicht automatisch, dass starke Psoriasis‑Beschwerden oder Neurodermitis unbehandelt bleiben müssen.[7][9][11][14][15] Es gibt mehrere Medikamente, bei denen die Daten zur Sicherheit in Bezug auf Tumor‑Rückfälle beruhigend sind.[7][9][11][15] Wichtig ist, dass Ihr Eurer Dermatologin oder Eurem Dermatologen jede frühere oder aktuelle Krebserkrankung mitteilt.[10][12][14] Die Fachleute empfehlen regelmäßige Krebs‑Vorsorge und ein genaues Beobachten von Veränderungen der Haut und des allgemeinen Befindens.[11][12] Für den Alltag heißt das: Therapie nicht eigenständig abbrechen, sondern Fragen offen ansprechen.[12][14] Pflege, Ernährung und Stressbewältigung bleiben wichtig, ersetzen aber keine ärztlich abgestimmte Behandlung.[10][11][12] Originaltitel: Targeted therapies for psoriasis and atopic dermatitis in the context of malignancy: SPIN-FRT recommendations Link zur Quelle

**Wie Hauterkrankungen Eure Arbeit beeinflussen** Immunschäden-bedingte Hauterkrankungen wie Schuppenflechte oder Neurodermitis belasten Eure **Arbeitsfähigkeit erheblich**. Über 65 % Betroffener geben eine mittlere bis starke Einschränkung im Berufsalltag an – durch Juckreiz, Schmerzen oder Erschöpfung[12]. Konzentrationsschwäche, Fehlzeiten und reduzierte Produktivität sind häufige Folgen[1][14]. **Praktische Lösungsansätze** Moderne gezielte Therapien (z. B. Antikörper-basierte Medikamente) können diese Belastung **deutlich mindern** und Eure Lebensqualität verbessern[8][13]. Doch bei rund einem Viertel der Patient:innen treten unerwartete Nebenwirkungen auf, die den Behandlungserfolg verzögern[12]. Wichtig: **Persönliche Therapiestrategien** sind entscheidend – sprecht mit Eurem Dermatologen über Eure Arbeitsanforderungen[13]. **Für den Alltag** - Dokumentiert Hautsymptome im Arbeitskontext (z. B. digitale Tagebücher) - Nutzt hautfreundliche Unterlagen bei körperlicher Tätigkeit - Klärt frühzeitig mit Arbeitgebern ab, ob flexible Pausen möglich sind[1][14] Eure Erfahrungen zählen: Regelmäßige Therapieanpassungen steigern die Erfolgschancen langfristig[13]. Bleibt geduldig – individuelle Lösungen brauchen Zeit. Originaltitel: Work impact of immune-mediated inflammatory skin diseases Link zur Quelle

**Hinweis zur Studie 42573454** Ich kann den Inhalt der konkreten PubMed‑Seite mit der PMID 42573454 technisch nicht direkt abrufen.[1][11] Damit ich Euch seriös und verständlich erklären kann, was die Studie für Euren Alltag mit Psoriasis oder Psoriasis‑Arthritis bedeutet, brauche ich den englischen Text. Bitte kopiert den Abstract oder die wichtigsten Textteile der Studie in Eure nächste Nachricht. Dann kann ich für Euch: - die Kernaussagen der Ergebnisse herausarbeiten - erklären, ob es eher um neue Medikamente, bekannte Wirkstoffe oder um Themen wie Pflege, Ernährung oder Lebensstil geht - in einfacher Sprache einordnen, was Ihr daraus konkret für Euren Alltag mitnehmen könnt. Originaltitel: 42573454 Link zur Quelle

BackgroundBiologics targeting key cytokines have enabled near-complete clearance in psoriasis treatment. As 90% reduction in the Psoriasis Area and Severity Index (PASI90) emerges as a meaningful goal of treatment, maintaining PASI90 without flare-up has become important.ObjectiveTo identify factors associated with PASI90 maintenance for ≥1 year without flare-up and predictors of drug discontinuation.MethodsThis multicenter retrospective cohort study included moderate-to-severe plaque psoriasis patients treated with adalimumab, ustekinumab, secukinumab, ixekizumab, guselkumab, or risankizumab (2010-2022). Treatment courses were defined as "Episodes." Patients with ≥2 years of therapy were analyzed. Relative risks (RR) for PASI90 maintenance were estimated using generalized linear mixed models, and Cox proportional hazards models assessed drug discontinuation.ResultsAmong 136 patients (189 episodes), 40.1% of 162 eligible episodes achieved PASI90 maintenance without flare-up for ≥1 year. Secukinumab significantly increased the likelihood of PASI90 maintenance (RR, 2.1; 95% confidence interval [CI], 1.27-3.49). Body mass index (BMI) <30 and first biologic episode showed favorable with only trend toward significance. Psoriasis Area and Severity Index response at week 16 and first assessment strongly predicted maintenance (area under the curve, 0.80-0.82). Regarding drug discontinuation, drug were discontinued in 28.6% of episodes; BMI ≥30, family history of psoriasis, and adalimumab (hazard ratio, 4.50; 95% CI, 1.57-12.90 vs. ustekinumab) were associated with higher risk of drug discontinuation.ConclusionSecukinumab, lower BMI, and biologic-naïve status favored durable PASI90 without flare-up. Obesity, family history, and adalimumab predicted drug discontinuation. Early treatment response strongly predicted long-term efficacy.Weiterlesen

Psoriatic arthritis is increasingly recognized as a systemic inflammatory disease with multiple comorbidities, yet the full spectrum of dental complications associated with psoriatic arthritis has not been clearly defined. This nationwide population based cohort study evaluated whether patients with psoriatic arthritis are at elevated risk of diverse dental diseases. Using a nationwide population-based health insurance database, we identified 40,920 newly diagnosed psoriatic arthritis cases and 204,468 age- and sex-matched controls. Dental outcomes included dental caries, pulp and periapical disease, periodontal disease, gingival changes and tooth loss. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs). PsA patients exhibited significantly increased risks of dental caries (aHR 1.342), pulp and periapical disease (aHR 1.633) and periodontal disease (aHR 1.268). Subtype analyses revealed elevated risks for acute and chronic gingivitis, aggressive and chronic periodontitis, periodontosis and unspecified periodontal disease. These findings highlight the need for comprehensive oral health surveillance in patients with psoriatic arthritis.Weiterlesen

BackgroundPsoriasis is a chronic immune‑mediated inflammatory skin disease that is strongly associated with metabolic dysregulation and excess adiposity. Dietary strategies that reduce energy intake either by continuous daily caloric restriction (CCR) or time‑limited/periodic intake such as intermittent fasting (IF) or ketogenic diets (Keto) may improve psoriasis severity through weight loss, metabolic improvements, alterations in gut microbiota, and immune-metabolic effects.ObjectiveWe aimed to compare the therapeutic effectiveness of IF, Keto, and CCR in reducing the severity of psoriasis.MethodsThis study was designed as a systematic review and Meta Analysis. The clinical parameters such as psoriasis extent and outcome measures were evaluated at baseline at different follow up timeframes across studies. Outcome measures were assessed by changes in Psoriasis Area and Severity Index (PASI) scores, quality of life (dermatology life quality index [DLQI]), and metabolic scores.ResultsThere was a significant PASI decrease in Keto and CCR cohorts (10-25.6 kg weight loss) compared with IF (0-2kg weight loss). No serious adverse effects were recorded in all interventions.LimitationsThe major limitations were study heterogeneity, lack of head-to-head comparisons, and follow up.ConclusionCCR and Keto performed better than IF in managing psoriasis severity, suggesting personalized dietary routines as adjuncts to treatment. &nbsp.Weiterlesen

During the phase III trial (NCT04839016), the outbreak of coronavirus disease 2019 (COVID-19) inevitably caused vunakizumab interruption in patients with psoriasis. This study extracted the data from Huashan Hospital, where almost all patients experienced drug interruption, and aimed to explore the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis and the impact of treatment interruption. A total of 90 patients with moderate-to-severe plaque psoriasis receiving vunakizumab (n = 65) or placebo (n = 25) were enrolled. Patients in the placebo group were switched to vunakizumab treatment at week (W)12. The 75% or more improvement in the Psoriasis Area Severity Index (PASI 75), PASI 90, and PASI 100 response rates at W12 were higher in the vunakizumab group than in the placebo group. This trend was observed at most time points over 52 weeks. Dermatology life quality index (DLQI) score, DLQI 0/1 response rate, and itch numerical rating scale score at W4, W8, and W12 were improved in the vunakizumab group compared to the placebo group. The incidence of adverse events during the induction period was numerically lower in the vunakizumab group than the placebo group. Sixty-four (98.5%) patients in the vunakizumab group experienced drug interruption, with 59 (92.2%) patients due to COVID-19 pandemic. All patients in the placebo group experienced any-cause drug interruption. In the vunakizumab group, elevated frequency of drug interruption was related to reduced PASI 75 and PASI 90 response rates at W52. Despite the high drug interruption rate in Huashan Hospital during COVID-19 pandemic, vunakizumab shows acceptable efficacy and safety for treating patients with moderate-to-severe plaque psoriasis. However, the long-term efficacy of vunakizumab appears attenuated in this single-center cohort compared with the overall phase III trial population.Weiterlesen

BackgroundPsoriasis is a chronic disease with a multidimensional impact that extends beyond skin symptoms, affecting physical, emotional, social well-being and satisfaction with care. This study aims to explore the perceived self-reported impact of psoriasis on patients' well-being across different life stages and to identify risk and protective factors associated with well-being over time.MethodsA cross-sectional observational study was conducted using an electronic questionnaire administered to adult patients with psoriasis and healthcare professionals involved in psoriasis management. Patients retrospectively self-reported the perceived impact of psoriasis on overall well-being and its physical, emotional, social, and treatment-related domains across consecutive 10-year life stages. Both patients and healthcare professionals evaluated perceived risk and protective factors for well-being.ResultsA total of 53 patients and 54 healthcare professionals completed the questionnaire. Most patients (90.6%) reported psoriasis had negatively affected their general well-being at some point during the disease course, with the physical (90.6%) and emotional (88.7%) domains being the most impacted. The highest perceived burden was reported between 31 and 40 years of age. Better reported symptom control was associated with lower perceived impairment in well-being. Key risk factors included affected body areas (95.3%), comorbidities (93.5%), and disease severity (89.7%), whereas appropriate treatment (96.3%), adequate medical care (93.5%), and a positive physician-patient relationship (89.7%) were identified as protective factors.ConclusionThese exploratory findings suggest that the self-reported perceived impact of psoriasis on well-being varies across life stages and is strongly influenced by symptom control and holistic disease management. These findings support a longitudinal, patient-centered approach to optimize long-term well-being.Weiterlesen

BackgroundDeucravacitinib, an oral tyrosine kinase 2 inhibitor, has demonstrated efficacy and safety in clinical trials; however, real-world evidence remains limited.ObjectiveTo evaluate real-world effectiveness, safety, and treatment persistence of deucravacitinib in Korean patients with plaque psoriasis.MethodsThis retrospective multicenter study included adults with plaque psoriasis treated with deucravacitinib at 3 tertiary hospitals. Efficacy was assessed using Psoriasis Area and Severity Index (PASI), body surface area, and Psoriasis Scalp Severity Index at baseline, 4-6, 10-12, and ≥13 months. PASI75 and PASI90 responses were analyzed using observed case (OC) and modified non-responder imputation (mNRI). Adverse events (AEs) and persistence were analyzed descriptively. Univariable and multivariable logistic regression analyses were performed to identify predictors of efficacy and AEs.ResultsForty-two patients (baseline PASI: 12.18±4.01) were included. PASI score decreased significantly to 3.42±3.10 at 4-6 months and 1.72±2.29 at 10-12 months. At 10-12 months, PASI75 and PASI90 response rates were 90.0% and 70.0% (OC; 18/20 and 14/20), and 75.0% and 58.3% (mNRI; 18/24 and 14/24). Thirteen patients (31.0%) reported AEs, primarily mucocutaneous and infectious; 3 patients discontinued deucravacitinib due to AEs. In both univariable and exploratory multivariable analyses, prior antihistamine use showed consistent borderline trends for PASI75 response, while male sex, increasing age, and shorter psoriasis duration showed borderline trends in either model. Treatment persistence was 73.2% at the last follow-up.ConclusionDeucravacitinib demonstrated consistent effectiveness, acceptable safety, and favorable persistence in routine Korean clinical practice, supporting its role as an oral treatment option for psoriasis.Weiterlesen

BackgroundPrimary cutaneous T-lymphomas (CTCL), particularly in their early stages, frequently present with clinical and histopathologic features that overlap with atopic dermatitis (AD) and psoriasis, contributing to diagnostic delay and ineffective, or even deleterious, treatment approaches. Thus, minimally invasive molecular tests capable of distinguishing CTCL from benign inflammatory dermatoses are urgently needed.ObjectivesTo determine whether tape strip transcriptomics can detect disease-specific signatures distinguishing early-stage CTCL from AD, psoriasis, and healthy control (HC) skin.MethodsBulk RNA sequencing was performed on lesional and non-lesional tape strips from patients with mycosis fungoides (MF) (n=18), AD (n=36), psoriasis (n=32), and HC skin (n=30).ResultsPrincipal component analysis revealed distinct clustering of MF, AD, and psoriasis lesional skin relative to HC. MF displayed a mixed immune profile, contrasting with the strong Th2 and Th17/Th22 immune polarization of AD and psoriasis, respectively. Upregulated MF genes were involved in immune checkpoint regulation (CTLA4, ICOS), lymphoid trafficking (CCR7, CCR8), antigen presentation (HLA-DRA, LAMP3), T-cell survival (TNFSF13B, BIRC3), metabolism (BCAT1, ENPP4, LIPA), as well as cell structure and homeostasis (CLIC2, DOCK10, EPB41L3, MCOLN2, MS4A14, S100B). We identified a 5-marker gene classifier (including IL36A) that accurately distinguished MF from both AD and psoriasis, which was validated in an independent dataset.ConclusionsBy capturing MF-specific signatures that are distinct from AD and psoriasis, tape stripping has the potential to serve as a diagnostic tool to help differentiate MF from its non-malignant mimickers.Weiterlesen

BackgroundPeople with psoriasis are at increased risk for nonmelanoma skin cancers (NMSC) and melanoma. Conventional immunosuppressants and TNF-α inhibitors may further increase skin malignancies, while the risks associated with other biologics are less clear. This study aimed to determine skin malignancy risks in psoriasis patients treated with cyclosporine, methotrexate, TNF-α inhibitors, IL-12/23, IL-17, and IL-23 inhibitors.MethodsUsing the TriNetX database, psoriasis patients without skin cancer risk factors who received at least 2 years or at least 5 years of systemic treatment were compared with non-systemically treated psoriasis patients. Cyclosporine, methotrexate, and TNF-α inhibitors were also compared with other psoriasis biologics. NMSC and melanoma over 2 and 5 years were evaluated using multivariable Cox proportional hazards.ResultsCompared with non-systemically treated psoriasis patients, cyclosporine, methotrexate, TNF-α inhibitors, and the IL-12/23 inhibitor showed increased NMSC risk, whereas IL-17 inhibitors demonstrated a reduced risk. Compared with patients treated with cyclosporine, methotrexate, and TNF-α inhibitors, both IL-17 and IL-23 inhibitors demonstrated a reduced NMSC risk. Only cyclosporine was associated with elevated melanoma risk. The present study is limited by unmeasured factors, including psoriasis severity, ultraviolet radiation exposure, medication adherence, and dosing.ConclusionsSystemic therapies for psoriasis vary in skin malignancy risk, with IL-17 and IL-23 inhibitors having the lowest NMSC risk. &nbsp.Weiterlesen

ObjectivesImmune mediated inflammatory diseases (IMID) affect women of childbearing age, yet there is a lack of evidence about the risk of adverse pregnancy outcomes and the interaction with medication. This study aims to characterise prescribing patterns and pregnancy outcomes in women with an IMID diagnosis.MethodsPregnancies to women with rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (PsO), spondyloarthritis (SpA) and inflammatory bowel disease (IBD) were identified within the Clinical Practice Research Datalink, between 01-Jan-2000 and 31-Jun-2020, and matched to pregnancies in women with no such diagnosis. Drug prescribing patterns were described during and surrounding pregnancy. The risk of spontaneous pregnancy loss and major congenital malformations (MCMs) were evaluated compared to women without an IMID. Exposure to commonly prescribed disease-modifying anti-rheumatic drugs was evaluated.ResultsThe risk of a spontaneous pregnancy loss ranged from HRadj 1.01 (CI950.79-1.28) for PsA to HRadj 1.18 (CI951.07-1.30) for IBD when compared to women without these conditions. No significant increases in the overall risk of MCMs were observed, with the exception of IBD where it reached borderline significance based on sensitivity analyses (ORadj 1.31 (CI951.00-1.71). No evidence of an increased risk of spontaneous loss was observed in women taking azathioprine, mesalazine and sulfasalazine.ConclusionWe found no increased risk of spontaneous loss in women with RA, PsA or SpA but a small increase in women with psoriasis or IBD. There was a borderline increased risk of all MCMs in offspring of women with IBD, which should be interpreted cautiously because of potential residual confounding.Weiterlesen

BackgroundThe emergence of new treatments has significantly elevated treatment expectations for psoriasis. However, existing Korean severity definitions and treatment targets of psoriasis remain primarily centered on traditional Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA) thresholds, often underestimating the disease burden in high-impact special areas.ObjectiveTo develop a revised Korean expert consensus on psoriasis severity and treatment targets that incorporate the clinical significance of special areas and reflect the evolving therapeutic landscape.MethodsA modified Delphi method was employed involving a panel of 65 dermatologists specializing in psoriasis from universities and training hospitals across South Korea. Two rounds of anonymous web-based surveys were conducted.ResultsA strong consensus was achieved on a new definition of moderate-to-severe psoriasis: (1) PASI ≥10, or (2) 5< PASI <10 with concomitant special area involvement (defined as ≥30% affected surface area of the specific site and a static Physician's Global Assessment (sPGA) score ≥3). For treatment targets, the panel established 'Absolute PASI ≤2' as the primary realistic goal. Site-specific goals were defined for special areas, to achieve an affected surface area <10% or an sPGA of 0/1. The Dermatology Life Quality Index was excluded from the mandatory severity definition or treatment target to preserve objectivity and feasibility in high-volume clinical settings.ConclusionThis consensus provides a practical and objective framework for managing psoriasis in Korea. These recommendations provide quantifiable criteria and stringent targets to optimize clinical decisions and patient outcomes in the era of advanced therapeutics.Weiterlesen

Die Studie EPOS hat sich Menschen mit langer Schuppenflechte und Gelenkschmerzen angesehen. Sie hatten noch keinen offiziellen Befund für Psoriasis Arthritis. Die Teilnehmenden nahmen 24 Wochen lang Apremilast Tabletten zweimal am Tag. Bilder von Händen und Knochen zeigten in dieser Zeit keine Verschlechterung an den Sehnenansätzen und keine neuen Schäden. Die Entzündung in den Bildern blieb gleich. Die Haut wurde deutlich besser und die Zahl der schmerzhaften Gelenke sank. Neue starke Nebenwirkungen traten nicht auf. Die Forschenden hoffen dass man mit solchen Behandlungen früh in den Krankheitsverlauf eingreifen kann, sicher ist das aber noch nicht. Originaltitel: Effect of apremilast on entheseal bone damage in psoriasis patients at risk of developing psoriatic arthritis - data from the prospective, interventional EPOS study. Link zur Quelle

Die Studie zeigt, dass das Prüfmedikament **socrodeucitinib** bei mittelschwerer bis schwerer Schuppenflechte deutlich besser wirkt als Placebo und bisher gut verträglich ist.[1] Für Euch bedeutet das vor allem neue Hoffnung auf weitere wirksame Tabletten, die aber noch erforscht werden müssen.[1] ### Was hat die Studie ergeben? In der Studie erhielten Menschen mit Plaque Psoriasis socrodeucitinib oder Placebo.[1] Nach 12 Wochen erreichten mit 6 mg etwa 29 von 100 und mit 12 mg über 72 von 100 eine deutliche Besserung der Haut (PASI 75).[1] Unter Placebo waren es nur rund 8 von 100.[1] Mit 12 mg hatten fast die Hälfte eine sehr starke Besserung (PASI 90) und einige eine komplett erscheinungsfreie Haut.[1] Die meisten Nebenwirkungen waren leicht oder mittel, schwere Nebenwirkungen traten selten auf.[1] ### Was heißt das für Euch? Socrodeucitinib ist noch nicht zugelassen. Es braucht größere und längere Studien.[1] Für Euren Alltag ändert sich im Moment nichts. Wichtig bleibt: gute Hautpflege, bekannte Auslöser meiden, vorhandene Therapien konsequent nutzen. Wenn Ihr Interesse an Studien habt, sprecht Eure dermatologische Praxis gezielt darauf an. Originaltitel: emJournal of the European Academy of Dermatology and Venereology/em | Wiley Online Library Link zur Quelle

Psoriasis betrifft weltweit über 60 Millionen Menschen, viele haben keinen Zugang zu modernen Biologika.[4] Die WHO hat nun die Biosimilars von **Adalimumab** und **Ustekinumab** in ihre Liste der unentbehrlichen Arzneimittel aufgenommen.[2][4] Forschende haben berechnet wie es wäre wenn viel mehr Menschen diese Mittel bekommen.[4] Bekämen 8,9 Millionen Erwachsene mit mittelschwerer bis schwerer Psoriasis die Therapie, gewönne jede Person im Schnitt deutlich Lebensqualität.[4] Im Modell sind das knapp 0,63 zusätzliche gesunde Lebensjahre pro Patient in fünf Jahren.[4] Weltweit ergäbe das über 5,5 Millionen solcher Lebensjahre und Gesundheitssysteme müssten dafür rund 124 Milliarden US Dollar zusätzlich ausgeben.[4] Das Modell geht von Idealbedingungen aus doch es zeigt wie stark mehr Biologika die Gesundheit von Menschen mit Psoriasis verbessern können besonders in ärmeren Ländern.[2][4] Originaltitel: Global health and economic impact of expanding the WHO essential medicines list for psoriasis: a health economic modelling study. Link zur Quelle

Ein neues Medikament gegen Psoriasis Arthritis zeigt nach einem Jahr gute Ergebnisse. In der Studie POETYK PsA‑1 bekamen 670 Erwachsene entweder Deucravacitinib als Tablette einmal täglich oder ein Scheinmedikament[3]. Nach 16 Wochen sprachen 54 von 100 Menschen mit Deucravacitinib an, mit Placebo nur 34[3][4]. Nach 52 Wochen ging es vielen noch besser und Gelenkschäden nahmen langsamer zu[3][4]. Schwere Nebenwirkungen traten selten auf und nicht häufiger als unter Placebo, es gab keine Todesfälle[3][4]. Deucravacitinib könnte damit eine weitere bequeme Therapie Option für Menschen mit Psoriasis Arthritis sein[3][4]. Originaltitel: Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial. Link zur Quelle

Deucravacitinib ist eine Tablette einmal täglich gegen mittelschwere bis schwere Plaque‑Psoriasis.[1] Neue Daten über bis zu fünf Jahre zeigen, dass das Mittel weiter gut wirkt.[1][3] Etwa zwei Drittel der Patienten behielten eine deutliche Besserung der Haut, viele waren fast erscheinungsfrei.[1][3] Auch die Lebensqualität blieb bei vielen deutlich besser.[1] Über 1500 Menschen nahmen teil, zusammen über 5000 Behandlungsjahre.[1][3] Schwere Nebenwirkungen traten selten auf und nahmen eher ab, neue Sicherheitsprobleme traten nicht auf.[1][3] Das spricht dafür, dass Deucravacitinib langfristig eine stabile und wirksame Option sein kann. Originaltitel: Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials. Link zur Quelle

https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-504417-67-00

Trial number: 2022-500408-22-00 Overall trial status: Ongoing, recruiting Trial title: OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1). Medical conditions: Plaque Psoriasis Status in each country: Germany:Ongoing, recruiting, Spain:Ongoing, recruiting, Poland:Ongoing, recruiting Trial phase: Therapeutic confirmatory (Phase III) Therapeutic Areas: Diseases [C] - Immune System Diseases [C20] Primary end point: Number of Participants With Adverse Events Secondary end point: N/A Age of participants: 0-17 years Gender of participants: Female, Male Trial region: In both EEA and non-EEA Planned number of participants: 70 Sponsor: Abbvie Deutschland GmbH & Co. KG Sponsor type: Pharmaceutical company Trial product: Risankizumab, ABBV-066 Results posted: No Overall decision date: 19/07/2022 Countries decision date: DE: 19/07/2022, ES: 19/07/2022, PL: 19/07/2022 Last updated date: 06/08/2026View the full article

Trial number: 2022-500408-22-00 Overall trial status: Ongoing, recruiting Trial title: OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1). Medical conditions: Plaque Psoriasis Status in each country: Germany:Ongoing, recruiting, Spain:Ongoing, recruiting, Poland:Ongoing, recruiting Trial phase: Therapeutic confirmatory (Phase III) Therapeutic Areas: Diseases [C] - Immune System Diseases [C20] Primary end point: Number of Participants With Adverse Events Secondary end point: N/A Age of participants: 0-17 years Gender of participants: Female, Male Trial region: In both EEA and non-EEA Planned number of participants: 70 Sponsor: Abbvie Deutschland GmbH & Co. KG Sponsor type: Pharmaceutical company Trial product: Risankizumab, ABBV-066 Results posted: No Overall decision date: 19/07/2022 Countries decision date: DE: 19/07/2022, ES: 19/07/2022, PL: 19/07/2022 Last updated date: 06/08/2026Den kompletten Artikel zeigen

Trial number: 2023-504417-67-00 Overall trial status: Ongoing, recruiting Trial title: An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment Medical conditions: Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis, Severe Chronic Plaque Psoriasis, Moderate to severe Chronic Plaque Psoriasis, Juvenile idiopathic Arthritis Status in each country: Czechia:Ongoing, recruiting, Spain:Ongoing, recruiting, Poland:Ongoing, recruiting, Bulgaria:Ongoing, recruiting, Italy:Ended, Portugal:Ended, Belgium:Authorised, recruitment pending, Germany:Authorised, recruitment pending Trial phase: Therapeutic use (Phase IV) Therapeutic Areas: Diseases [C] - Immune System Diseases [C20] Primary end point: Serious adverse events (SAEs), adverse events (AEs), and injection site reactions Secondary end point: N/A Age of participants: 18-64 years, 65+ years, 0-17 years Gender of participants: Female, Male Trial region: In both EEA and non-EEA Planned number of participants: 328 Sponsor: Novartis Pharma AG Sponsor type: Pharmaceutical company Trial product: SECUKINUMAB, SECUKINUMAB Results posted: No Overall decision date: 21/08/2023 Countries decision date: IT: 09/07/2024, PT: 12/06/2024, BG: 20/09/2023, CZ: 21/08/2023, PL: 23/08/2023, ES: 22/08/2023, DE: 06/08/2026, BE: 19/11/2025 Last updated date: 06/08/2026Den kompletten Artikel zeigen

Viele Hautprobleme können zeigen dass mit Darm oder Leber etwas nicht stimmt[5][9]. Bei chronisch entzündlichen Darmerkrankungen treten oft schmerzhafte Knoten an den Beinen oder offene Hautgeschwüre auf[1][4]. Autoimmunleberkrankheiten gehen häufig mit Hidradenitis suppurativa Vitiligo Psoriasis oder kreisrundem Haarausfall einher[5][10]. Bestimmte Hepatitisformen lösen manchmal Lichen planus oder eine besondere Lichtempfindlichkeit der Haut aus[2][14]. Wenn der Darm Nährstoffe schlecht aufnimmt zeigt das sich oft an der Haut, mit Zeichen von Zöliakie Zinkmangel Pellagra oder Skorbut[5][15]. Medikamente gegen Darm oder Leber können Ausschläge auslösen oder sogar eine neue Psoriasis hervorrufen[5][15]. Daher sollten Ärztinnen und Ärzte auf neue Flecken Knoten oder Geschwüre achten und rechtzeitig handeln[14][16]. Originaltitel: [Cutaneous presentation of digestive tract disorders and liver disease]. Link zur Quelle

Forscher haben einen neuen Wirkstoff gegen Psoriasis getestet. Er heißt **CPD3a** und stammt aus Cordycepin aus dem Pilz Cordyceps militaris. Cordycepin bremst Entzündungen, wird im Körper aber schnell abgebaut[6]. CPD3a bleibt stabil und wirkt stark entzündungshemmend. Die Forscher packten CPD3a in winzige Pflaster mit **Mikronadeln** für die Haut. In einem Mausmodell mit Psoriasis wurden die Schuppen und Rötungen deutlich weniger. Die Hautschicht wurde dünner und der ganze Körper zeigte weniger Entzündung. Außerdem geriet das Immunsystem wieder mehr ins Gleichgewicht. Bis jetzt gibt es nur Daten aus Tierversuchen, Menschen können das noch nicht anwenden. Trotzdem zeigt die Studie einen spannenden Ansatz für neue lokale Therapien. Originaltitel: A C-Nucleoside Analogue of Cordycepin With High Metabolic Stability and Potent Anti-Psoriatic Activity via Microneedle Delivery. Link zur Quelle